Trading Report: Today, State of Wisconsin Investment Board Sold shares of Qiagen NV (QGEN)

Today, State of Wisconsin Investment Board Sold shares of Qiagen NV (QGEN)

State of Wisconsin Investment Board lowered its position in Qiagen NV (NASDAQ:QGEN) by 1.8% during the third quarter, Holdings Channel reports. The institutional investor owned 146,070 shares of the company’s stock after selling 2,700 shares during the period. State of Wisconsin Investment Board’s holdings in Qiagen NV were worth $4,008,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. SG Americas Securities LLC raised its stake in Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock worth $152,000 after buying an additional 629 shares during the period. Emerald Acquisition Ltd. bought a new stake in Qiagen NV during the second quarter worth approximately $11,027,000. RMB Capital Management LLC bought a new stake in Qiagen NV during the second quarter worth approximately $559,000. Swiss National Bank raised its stake in Qiagen NV by 3.3% in the second quarter. Swiss National Bank now owns 1,492,675 shares of the company’s stock worth $32,304,000 after buying an additional 48,145 shares during the period. Finally, Gratus Capital LLC bought a new stake in Qiagen NV during the second quarter worth approximately $438,000. Institutional investors and hedge funds own 57.33% of the company’s stock.

Shares of Qiagen NV (NASDAQ:QGEN) traded down 1.67% during midday trading on Monday, hitting $27.10. The company had a trading volume of 764,289 shares. Qiagen NV has a 52 week low of $19.94 and a 52 week high of $28.50. The firm’s 50 day moving average is $26.50 and its 200 day moving average is $24.74. The company has a market capitalization of $6.35 billion, a P/E ratio of 54.20 and a beta of 1.07.

Qiagen NV (NASDAQ:QGEN) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.01. Qiagen NV had a return on equity of 9.34% and a net margin of 8.96%. The business had revenue of $338.70 million for the quarter, compared to the consensus estimate of $335.46 million. During the same quarter last year, the business posted $0.27 earnings per share. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. Equities research analysts anticipate that Qiagen NV will post $1.03 EPS for the current year.

A number of equities research analysts have commented on QGEN shares. Zacks Investment Research upgraded Qiagen NV from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Wednesday, August 3rd. HSBC upgraded Qiagen NV from a “hold” rating to a “buy” rating in a research report on Monday, August 1st. Morgan Stanley set a $30.00 price target on Qiagen NV and gave the company a “buy” rating in a research report on Sunday, September 11th. DZ Bank AG reiterated a “buy” rating on shares of Qiagen NV in a research report on Monday, September 12th. Finally, Commerzbank AG reiterated a “buy” rating on shares of Qiagen NV in a research report on Friday, September 9th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $26.60.

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

Related posts

Leave a Comment